Cargando…

Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report

Peritoneal mesotheliomas are very rare tumors. Their prognosis is poor, average survival does not exceed 1 year after peritoneal cytoreduction. Systemic chemotherapy is considered to have no proven value in the management of peritoneal mesotheliomas. Objective responses with systemic chemotherapy ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Elghali, Mohamed Amine, Bourigua, Rym, Belaid, Imtinene, Nasri, Salsabil, Mestiri, Sara, Yaacoub, Sara, Makni, Amine, Letaief, Rached
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874336/
https://www.ncbi.nlm.nih.gov/pubmed/33613924
http://dx.doi.org/10.1177/2036361320984527
_version_ 1783649571755261952
author Elghali, Mohamed Amine
Bourigua, Rym
Belaid, Imtinene
Nasri, Salsabil
Mestiri, Sara
Yaacoub, Sara
Makni, Amine
Letaief, Rached
author_facet Elghali, Mohamed Amine
Bourigua, Rym
Belaid, Imtinene
Nasri, Salsabil
Mestiri, Sara
Yaacoub, Sara
Makni, Amine
Letaief, Rached
author_sort Elghali, Mohamed Amine
collection PubMed
description Peritoneal mesotheliomas are very rare tumors. Their prognosis is poor, average survival does not exceed 1 year after peritoneal cytoreduction. Systemic chemotherapy is considered to have no proven value in the management of peritoneal mesotheliomas. Objective responses with systemic chemotherapy are very rare. We report here a case of an advanced peritoneal mesothelioma which achieved an unexpected partial response with chemotherapy, allowing the patient to have a right colectomy. The patient was referred to a specialized center on HIPEC, but taking in account the long awaiting interval, the HIPEC was judged to be inefficient and then the poursuit of 6 cycles of systemic chemotherapy was decided. The patient is still alive without any symptom and with a good performance status at 59 months after diagnosis. Throughout our case, we provide an encouraging evidence of the role of initial systemic chemotherapy in the downstaging of initially unresectable primary malignant mesothelioma and in the improvement of overall survival.
format Online
Article
Text
id pubmed-7874336
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-78743362021-02-19 Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report Elghali, Mohamed Amine Bourigua, Rym Belaid, Imtinene Nasri, Salsabil Mestiri, Sara Yaacoub, Sara Makni, Amine Letaief, Rached Rare Tumors Case Report Peritoneal mesotheliomas are very rare tumors. Their prognosis is poor, average survival does not exceed 1 year after peritoneal cytoreduction. Systemic chemotherapy is considered to have no proven value in the management of peritoneal mesotheliomas. Objective responses with systemic chemotherapy are very rare. We report here a case of an advanced peritoneal mesothelioma which achieved an unexpected partial response with chemotherapy, allowing the patient to have a right colectomy. The patient was referred to a specialized center on HIPEC, but taking in account the long awaiting interval, the HIPEC was judged to be inefficient and then the poursuit of 6 cycles of systemic chemotherapy was decided. The patient is still alive without any symptom and with a good performance status at 59 months after diagnosis. Throughout our case, we provide an encouraging evidence of the role of initial systemic chemotherapy in the downstaging of initially unresectable primary malignant mesothelioma and in the improvement of overall survival. SAGE Publications 2021-02-04 /pmc/articles/PMC7874336/ /pubmed/33613924 http://dx.doi.org/10.1177/2036361320984527 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Elghali, Mohamed Amine
Bourigua, Rym
Belaid, Imtinene
Nasri, Salsabil
Mestiri, Sara
Yaacoub, Sara
Makni, Amine
Letaief, Rached
Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report
title Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report
title_full Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report
title_fullStr Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report
title_full_unstemmed Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report
title_short Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report
title_sort prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874336/
https://www.ncbi.nlm.nih.gov/pubmed/33613924
http://dx.doi.org/10.1177/2036361320984527
work_keys_str_mv AT elghalimohamedamine prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport
AT bouriguarym prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport
AT belaidimtinene prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport
AT nasrisalsabil prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport
AT mestirisara prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport
AT yaacoubsara prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport
AT makniamine prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport
AT letaiefrached prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport